Abstract:
Tafenoquine (TQ), as a single dose regimen, has significant advantages over the longer courses
of primaquine (PQ) needed to achieve radical cure of P. vivax. The current data available show
that the recommended fixed dose of 300mg TQ in adults is too low and compromised by a lack
of weight-based dosing. To ensure maximal impact on health outcomes, the recommended dose
for TQ must be optimized for clinical practice. Our study will assess the efficacy and safety of
a higher weight based TQ dose regimen.
